HK Stock Market Move | WUXI XDC (02268) rose more than 8% during the trading day. The company is expected to continue benefiting from the improving trend of downstream demand in the XDC CRDMO industry.

WUXI XDC (02268) rose more than 8% in midday trading, up 6.6% to HK$62.2 as of the time of publication, with a turnover of HK$253 million. On the news front, WUXI XDC previously released a positive performance forecast for 2025. BOCOM INTL stated that based on the company's profit forecast, it has slightly lowered its revenue and adjusted net profit forecasts for 2025-27 by 1-3% to RMB 58.8 billion/82.8 billion/111.1 billion, and RMB 16.0 billion/24.5 billion/34.2 billion, respectively, corresponding to a 38%/46% CAGR in 2025-27. The strong growth is mainly due to the rapid growth of comprehensive CMC orders, especially the increase in the contribution of late-stage clinical/commercial phase orders. BOCOM INTL pointed out that according to statistics, there have been 25 investment and financing events in the global XDC track in the first two months of 2026, a significant increase from the 18 events in the same period in 2025. BD transactions of XDC candidate drugs have shown a similar trend, with the number of transactions remaining stable and the total amount of down payments increasing significantly. Since the beginning of 2024, the number of investment and financing events in the XDC field, BD transactions, and total down payments have been gradually increasing. The continued activity in investment and financing and BD transactions will further drive the improvement in downstream demand in the XDC CRDMO industry. As a leading company in technology strength and integrated delivery capability, WUXI XDC is expected to continue to benefit from this important trend and expand its market share.